A deal with Shanghai Jemincare Pharmaceutical has filled the hole. Rapt is paying $35 million upfront, plus up to $672.5 ...

RAPT Therapeutics and Shanghai Jemincare Pharmaceutical have signed an exclusive agreement for the clinical-stage ...

A breach in the gut immunity and crossreactivity of the IgE antibodies with skin antigens or direct interaction with specific IgE, Fc receptors on Langerhans cells, mast cells, monocytes ...

If your drug trials don't succeed, try again with another drug — and raise more money. That's $RAPT's plan as it targets food ...

The biologic seemed to express an epitope to alpha-1,3-galactose (alpha-gal) that IgE antibodies recognize in people with alpha-gal syndrome (AGS), reported Preethi Venkat, MD, MPH, of the ...

Jemincare is currently conducting Phase 2 trials in asthma and chronic spontaneous urticaria in China - - RAPT plans to initiate Phase 2b trial in food allergy next year - SOUTH SAN FRANCISCO, Calif., ...

RAPT Therapeutics, Inc. (NASDAQ:RAPT) shares are trading higher after the company disclosed a partnership with Shanghai ...

The dvm360 editorial team is counting down our Top 20 news stories and articles of the year, from January 1, 2024, to ...

RAPT Therapeutics (RAPT), and Shanghai Jemincare Pharmaceutical Co., a subsidiary of Jiangxi Jemincare Group, have entered into an ...

RPT904 is being developed to offer patients a potentially improved therapeutic option compared to omalizumab (marketed as Xolair®), an anti-IgE monoclonal antibody approved for several allergic ...